These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Effect of electroacupuncture scalp point-through-point therapy on the expression of tyrosine hydroxylase and dopamine transporter mRNAs in substantia nigra of Parkinson's disease model rats]. Wang S; Qi XJ; Han D Zhongguo Zhen Jiu; 2009 May; 29(5):391-4. PubMed ID: 19489498 [TBL] [Abstract][Full Text] [Related]
24. Role of histaminergic system in blood-brain barrier dysfunction associated with neurological disorders. Bañuelos-Cabrera I; Valle-Dorado MG; Aldana BI; Orozco-Suárez SA; Rocha L Arch Med Res; 2014 Nov; 45(8):677-86. PubMed ID: 25446620 [TBL] [Abstract][Full Text] [Related]
25. Blood-brain barrier alterations in ageing and dementia. Popescu BO; Toescu EC; Popescu LM; Bajenaru O; Muresanu DF; Schultzberg M; Bogdanovic N J Neurol Sci; 2009 Aug; 283(1-2):99-106. PubMed ID: 19264328 [TBL] [Abstract][Full Text] [Related]
26. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease. Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945 [TBL] [Abstract][Full Text] [Related]
27. Plasma levels of lipid peroxides in patients with Parkinson's disease. Sanyal J; Bandyopadhyay SK; Banerjee TK; Mukherjee SC; Chakraborty DP; Ray BC; Rao VR Eur Rev Med Pharmacol Sci; 2009; 13(2):129-32. PubMed ID: 19499848 [TBL] [Abstract][Full Text] [Related]
28. Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model. Jeon S; Kim YJ; Kim ST; Moon W; Chae Y; Kang M; Chung MY; Lee H; Hong MS; Chung JH; Joh TH; Lee H; Park HJ Proteomics; 2008 Nov; 8(22):4822-32. PubMed ID: 18942673 [TBL] [Abstract][Full Text] [Related]
29. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575 [TBL] [Abstract][Full Text] [Related]
30. Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. Verma R; Nehru B Neurochem Int; 2009 Nov; 55(6):369-75. PubMed ID: 19375462 [TBL] [Abstract][Full Text] [Related]
31. Nuclear accumulation of GAPDH, GluA2 and p53 in post-mortem substantia nigral region of patients with Parkinson's disease. Sekar S; Taghibiglou C Neurosci Lett; 2020 Jan; 716():134641. PubMed ID: 31759082 [TBL] [Abstract][Full Text] [Related]
32. Near-infrared fluorescence imaging with fluorescently labeled albumin: a novel method for non-invasive optical imaging of blood-brain barrier impairment after focal cerebral ischemia in mice. Klohs J; Steinbrink J; Bourayou R; Mueller S; Cordell R; Licha K; Schirner M; Dirnagl U; Lindauer U; Wunder A J Neurosci Methods; 2009 May; 180(1):126-32. PubMed ID: 19427539 [TBL] [Abstract][Full Text] [Related]
33. Post-ischemic leakiness of the blood-brain barrier: a quantitative and systematic assessment by Patlak plots. Abo-Ramadan U; Durukan A; Pitkonen M; Marinkovic I; Tatlisumak E; Pedrono E; Soinne L; Strbian D; Tatlisumak T Exp Neurol; 2009 Sep; 219(1):328-33. PubMed ID: 19520075 [TBL] [Abstract][Full Text] [Related]
34. Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Stolp HB; Dziegielewska KM Neuropathol Appl Neurobiol; 2009 Apr; 35(2):132-46. PubMed ID: 19077110 [TBL] [Abstract][Full Text] [Related]
35. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease. Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598 [TBL] [Abstract][Full Text] [Related]
36. Diffusion tensor imaging in a rat model of Parkinson's disease after lesioning of the nigrostriatal tract. Van Camp N; Blockx I; Verhoye M; Casteels C; Coun F; Leemans A; Sijbers J; Baekelandt V; Van Laere K; Van der Linden A NMR Biomed; 2009 Aug; 22(7):697-706. PubMed ID: 19378292 [TBL] [Abstract][Full Text] [Related]
37. The protective effect of vitamin E on locus coeruleus in early model of Parkinson's disease in rat: immunoreactivity evidence. Pasbakhsh P; Omidi N; Mehrannia K; Sobhani AG; Ragerdi Kashani I; Abbasi M; Kord Valeshabad A Iran Biomed J; 2008 Oct; 12(4):217-22. PubMed ID: 19079535 [TBL] [Abstract][Full Text] [Related]
38. Impact of glucocorticoids and chronic stress on progression of Parkinson's disease. Kibel A; Drenjancević-Perić I Med Hypotheses; 2008 Dec; 71(6):952-6. PubMed ID: 18718724 [TBL] [Abstract][Full Text] [Related]
39. Parkinson's disease: the syndrome, the pathogenesis and pathophysiology. Bartels AL; Leenders KL Cortex; 2009 Sep; 45(8):915-21. PubMed ID: 19095226 [TBL] [Abstract][Full Text] [Related]
40. Anti-melanin antibodies are increased in sera in Parkinson's disease. Double KL; Rowe DB; Carew-Jones FM; Hayes M; Chan DK; Blackie J; Corbett A; Joffe R; Fung VS; Morris J; Riederer P; Gerlach M; Halliday GM Exp Neurol; 2009 Jun; 217(2):297-301. PubMed ID: 19289120 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]